FDA RECALLS & COURT ACTIONS: September 15, 1993
Executive Summary
CLASS II -- CEFZIL (CEPROZIL HCL) 500 mg unit dose tablets, a broad spectrum antibiotic. Recall number: D-333-3. Lot numbers: B2V77A EXP 3/94, C2W64B EXP 4/94. Manufacturer: Bristol-Myers Carceloneta, Barceloneta, Puerto Rico. Recalled by: Bristol-Myers Squibb Company, New Brunswick, New Jersey, by letter dated Aug. 18, 1993. Firm-initiated recall ongoing. Distribution: Nationwide; 922 units of lot B2V77A, 449 units of lot C2W64B were distributed. Reason: Strips of 500 mg unit- dose tablets were packaged in some cartons labeled as 250 mg. CLASS III -- KONDREMUL PLAIN In 16 ounce bottles, used for the temporary relief of constipation and sold under Fisons label. Recall number: D-337-3. Lot number RK2065 EXP 9/95 (Fisons lot 38487). Manufacturer: Barre-National, Inc., Baltimore, Maryland. Recalled by: Manufacturer, by letter April 7, 1993. Firm-initiated recall complete. Distribution: Now York; 60,864 units were distributed; firm estimates none remains on the market. Reason: Product fails stability specifications for total microbial count. CLASS III -- SODIUM POLYSTYRENE SULFONATE SUSPENSION, USP In 1 pint and 60 ml plastic bottles. Recall number: D-335-3. All lots. Manufacturer: Carolina Medical Products Company, Farmville, North Carolina. Recalled by: Manufacturer, by telephone Aug. 30, 1993, and by letter Aug. 31, 1993. Firm-initiated recall ongoing. Distribution: Canada; firm estimates 200 pint bottles and 75 10- bottle cartons of 60 ml bottles remain on the market. Reason: Use of non-approved formulation.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth